EA018974B9 - Твердые лекарственные формы - Google Patents
Твердые лекарственные формыInfo
- Publication number
- EA018974B9 EA018974B9 EA201070713A EA201070713A EA018974B9 EA 018974 B9 EA018974 B9 EA 018974B9 EA 201070713 A EA201070713 A EA 201070713A EA 201070713 A EA201070713 A EA 201070713A EA 018974 B9 EA018974 B9 EA 018974B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- solid state
- androstane
- ethynyl
- diol
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
- C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0048—Alkynyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2647208P | 2008-02-05 | 2008-02-05 | |
| US9369408P | 2008-09-02 | 2008-09-02 | |
| PCT/US2009/033280 WO2009100258A1 (en) | 2008-02-05 | 2009-02-05 | Pharmaceutical solid state forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201070713A1 EA201070713A1 (ru) | 2011-08-30 |
| EA018974B1 EA018974B1 (ru) | 2013-12-30 |
| EA018974B9 true EA018974B9 (ru) | 2014-04-30 |
Family
ID=40952461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201070713A EA018974B9 (ru) | 2008-02-05 | 2009-02-05 | Твердые лекарственные формы |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8518922B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2249838A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011511011A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100113602A (cg-RX-API-DMAC7.html) |
| CN (2) | CN103467554A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009212314C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2712005C (cg-RX-API-DMAC7.html) |
| EA (1) | EA018974B9 (cg-RX-API-DMAC7.html) |
| IL (1) | IL207378A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009100258A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| CA2728889C (en) * | 2008-04-03 | 2016-06-14 | Harbor Biosciences, Inc. | Solid state forms of a pharmaceutical |
| WO2011066582A1 (en) * | 2009-11-30 | 2011-06-03 | Harbor Biosciences, Inc. | Anticancer compounds and screening method |
| EP2524059A4 (en) | 2010-01-13 | 2013-11-20 | Caris Life Sciences Luxembourg Holdings | DETECTION OF GASTROINTESTINAL DISEASES |
| AU2011223789A1 (en) | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| AU2011343599A1 (en) * | 2010-12-17 | 2013-05-09 | Harbor Biosciences, Inc. | Steroid tetrol solid state forms |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CN104173353B (zh) * | 2013-05-22 | 2018-08-21 | 中国医药工业研究总院 | 不含表面活性剂的固体制剂及其制备方法 |
| CA2930199C (en) * | 2013-11-12 | 2022-10-25 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
| CN105434444B (zh) * | 2014-09-29 | 2021-02-05 | 上海奥奇医药科技有限公司 | 一种A-失碳-5α雄甾烷化合物的口服制剂 |
| RU2017112748A (ru) | 2014-11-17 | 2018-12-19 | Арно Терапьютикс, Инк. | Композиции онапристона пролонгированного действия и способы |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| HK1255104A1 (zh) | 2015-12-15 | 2019-08-02 | Context Biopharma Inc. | 无定形的奥那司酮组合物及其制备方法 |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| DK3601265T3 (da) * | 2017-03-30 | 2023-09-18 | Merck Patent Gmbh | Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol |
| RU2668526C1 (ru) * | 2017-08-18 | 2018-10-01 | Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения | Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах |
| KR20210111254A (ko) | 2018-11-30 | 2021-09-10 | 캐리스 엠피아이, 아이엔씨. | 차세대 분자 프로파일링 |
| CN111773388B (zh) * | 2019-04-04 | 2023-07-18 | 上海奥奇医药科技有限公司 | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 |
| IL293489A (en) | 2019-12-02 | 2022-08-01 | Caris Mpi Inc | predictor of pan-cancer platinum response |
| MX2022009999A (es) | 2020-02-14 | 2023-01-19 | Caris Mpi Inc | Puntuacion de prevalencia genomica panomica. |
| US20260157968A1 (en) * | 2024-12-11 | 2026-06-11 | Americana Pharma Llc | Method and Composition for an Improved Bioavailability Delivery System |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040224932A1 (en) * | 2000-08-05 | 2004-11-11 | Keith Biggadike | Novel anti-inflammatory androstane derivative compositions |
| US20070129548A1 (en) * | 2005-12-07 | 2007-06-07 | Lushi Tan | Polymorphs of an androgen receptor modulator |
| US20080021006A1 (en) * | 1999-09-30 | 2008-01-24 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical Compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE681869C (de) * | 1935-11-22 | 1939-10-03 | Schering Ag | Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe |
| CH202847A (de) | 1937-06-26 | 1939-02-15 | Chem Ind Basel | Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe. |
| WO1994005630A1 (en) | 1992-08-28 | 1994-03-17 | Lunar Corporation | 1α,24(S)-DIHYDROXY VITAMIN D2, ITS FORMATION AND USE |
| US5567830A (en) * | 1994-02-14 | 1996-10-22 | Cocensys, Inc. | Process for synthesis of acetylenic carbinols |
| PT889889E (pt) | 1996-03-29 | 2007-01-31 | Duphar Int Res | Composto de piperazina e piperidina |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| US7045513B1 (en) | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| EP1591121B1 (en) | 2000-12-14 | 2009-06-24 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form |
| AR034206A1 (es) | 2001-02-16 | 2004-02-04 | Solvay Pharm Bv | Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos |
| DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
| US7540016B2 (en) * | 2004-07-21 | 2009-05-26 | Beachhead Solutions, Inc. | System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall |
| US7964604B2 (en) | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
| TWI305979B (en) * | 2006-03-24 | 2009-02-01 | Hon Hai Prec Ind Co Ltd | Wireless transceiving system |
| CN103211821A (zh) * | 2006-04-22 | 2013-07-24 | 霍利斯—伊登医药公司 | 药物和用途 |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
-
2009
- 2009-02-05 CA CA2712005A patent/CA2712005C/en not_active Expired - Fee Related
- 2009-02-05 CN CN2013102558234A patent/CN103467554A/zh active Pending
- 2009-02-05 AU AU2009212314A patent/AU2009212314C1/en not_active Ceased
- 2009-02-05 KR KR1020107019161A patent/KR20100113602A/ko not_active Ceased
- 2009-02-05 EP EP09709386A patent/EP2249838A4/en not_active Withdrawn
- 2009-02-05 WO PCT/US2009/033280 patent/WO2009100258A1/en not_active Ceased
- 2009-02-05 EA EA201070713A patent/EA018974B9/ru not_active IP Right Cessation
- 2009-02-05 CN CN200980104255XA patent/CN101939009B/zh not_active Expired - Fee Related
- 2009-02-05 JP JP2010545285A patent/JP2011511011A/ja active Pending
- 2009-02-12 US US12/370,510 patent/US8518922B2/en active Active
-
2010
- 2010-08-03 IL IL207378A patent/IL207378A0/en unknown
-
2013
- 2013-06-17 US US13/919,386 patent/US20130345184A1/en not_active Abandoned
- 2013-06-17 US US13/919,593 patent/US9314471B2/en active Active - Reinstated
- 2013-06-17 US US13/919,728 patent/US20130338125A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080021006A1 (en) * | 1999-09-30 | 2008-01-24 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical Compositions |
| US20040224932A1 (en) * | 2000-08-05 | 2004-11-11 | Keith Biggadike | Novel anti-inflammatory androstane derivative compositions |
| US20070129548A1 (en) * | 2005-12-07 | 2007-06-07 | Lushi Tan | Polymorphs of an androgen receptor modulator |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103467554A (zh) | 2013-12-25 |
| KR20100113602A (ko) | 2010-10-21 |
| US9314471B2 (en) | 2016-04-19 |
| CN101939009A (zh) | 2011-01-05 |
| EA201070713A1 (ru) | 2011-08-30 |
| AU2009212314A1 (en) | 2009-08-13 |
| US20090291932A1 (en) | 2009-11-26 |
| EA018974B1 (ru) | 2013-12-30 |
| US8518922B2 (en) | 2013-08-27 |
| CA2712005C (en) | 2014-04-15 |
| US20130338125A1 (en) | 2013-12-19 |
| WO2009100258A1 (en) | 2009-08-13 |
| EP2249838A1 (en) | 2010-11-17 |
| IL207378A0 (en) | 2010-12-30 |
| CA2712005A1 (en) | 2009-08-13 |
| CN101939009B (zh) | 2013-07-17 |
| JP2011511011A (ja) | 2011-04-07 |
| HK1147695A1 (en) | 2011-08-19 |
| AU2009212314B2 (en) | 2013-11-21 |
| EP2249838A4 (en) | 2012-05-02 |
| AU2009212314C1 (en) | 2014-05-08 |
| US20130345184A1 (en) | 2013-12-26 |
| US20130345455A1 (en) | 2013-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2249838A4 (en) | Pharmaceutical solid state forms | |
| SG178986A1 (en) | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | |
| PH12013502369A1 (en) | Diazacarbazoles and methods of use | |
| MX2012006822A (es) | 1,7-diazacarbazoles y metodos de uso. | |
| MX2020012825A (es) | Compuestos multiciclicos y metodos de uso de los mismos. | |
| SI2444085T1 (sl) | Diarilhidantoinske spojine kot antagonisti androgenega receptorja za zdravljenje raka | |
| EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
| JO2787B1 (en) | Alternative amide derivatives and methods of use | |
| TN2012000171A1 (en) | Synthetic methods for spiro-oxindole compounds | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| MY161549A (en) | Progesterone antagonists such as cdb-4124 in the treatment of breast cancer | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| MX2009000531A (es) | Derivados heterociclicos fusionados y metodos de uso. | |
| PH12014502133B1 (en) | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | |
| MX2009013321A (es) | Derivados de espiro[piperidin-4,4'-tieno[3,2-c]pirano] y compuestos relacionados como inhibidores del receptor sigma para el tratamiento de psicosis. | |
| UA96447C2 (ru) | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы | |
| MX2012002327A (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. | |
| MX2010010799A (es) | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. | |
| WO2008060945A3 (en) | Diagnosis and treatment of breast cancer | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| WO2010099003A3 (en) | Compositions and methods for visualizing and eliminating cancer stem cells | |
| MX342459B (es) | 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3. | |
| IL206738A0 (en) | Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | |
| EP2124554A4 (en) | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | |
| MX2013002295A (es) | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |